Enhanced luminal breast tumor response to antiestrogen therapy

Breast cancer can be divided into 4 major subtypes using molecular and genetic information from the tumors. Each subtype is associated with different prognosis and should be taken into consideration when making treatment decisions.

In this issue of the Journal of Clinical Investigation, Rebecca Cook and colleagues at Vanderbilt University, found that expression of an oncogene, ERBB3, was enhanced in luminal breast cancers compared to other subtypes. Addition of the ERBB3 protein to cultured luminal increased the growth of the cells; however, depletion of this protein with an antibody promoted cancer cell death, and decreased tumor growth in vitro.

The authors also demonstrated that ERBB3 was upregulated in luminal tumor samples and in cancer cell cultures that were treated with the cancer drug fulvestrant. Furthermore, the authors found that fulvestrant treatment in combination with anti-ERBB3 decreased both tumor cell survival and growth.

These data suggests that ERBB3 could be a target for treatment of fulvestrant resistant breast cancers.


Explore further

Black women have worse breast cancer mortality regardless of cancer subtype

More information: ErbB3 downregulation enhances luminal breast tumor response to antiestrogens, J Clin Invest. DOI: 10.1172/JCI66764
Citation: Enhanced luminal breast tumor response to antiestrogen therapy (2013, September 3) retrieved 19 October 2019 from https://medicalxpress.com/news/2013-09-luminal-breast-tumor-response-antiestrogen.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more